UniQure Shares Outstanding 2013-2022 | QURE
UniQure shares outstanding from 2013 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
UniQure Annual Shares Outstanding (Millions of Shares) |
2021 |
47 |
2020 |
44 |
2019 |
40 |
2018 |
36 |
2017 |
27 |
2016 |
25 |
2015 |
22 |
2014 |
17 |
2013 |
11 |
2012 |
9 |
UniQure Quarterly Shares Outstanding (Millions of Shares) |
2022-03-31 |
47 |
2021-12-31 |
47 |
2021-09-30 |
46 |
2021-06-30 |
47 |
2021-03-31 |
45 |
2020-12-31 |
44 |
2020-09-30 |
44 |
2020-06-30 |
44 |
2020-03-31 |
44 |
2019-12-31 |
40 |
2019-09-30 |
41 |
2019-06-30 |
38 |
2019-03-31 |
38 |
2018-12-31 |
36 |
2018-09-30 |
37 |
2018-06-30 |
36 |
2018-03-31 |
32 |
2017-12-31 |
27 |
2017-09-30 |
26 |
2017-06-30 |
26 |
2017-03-31 |
25 |
2016-12-31 |
25 |
2016-09-30 |
25 |
2016-06-30 |
25 |
2016-03-31 |
25 |
2015-12-31 |
22 |
2015-09-30 |
21 |
2015-06-30 |
22 |
2015-03-31 |
18 |
2014-12-31 |
18 |
2014-09-30 |
18 |
2014-06-30 |
18 |
2014-03-31 |
15 |
2013-12-31 |
|
2013-09-30 |
|
2012-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Biomedical and Genetics |
$0.640B |
$0.524B |
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|